Relative abuse liability of γ-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users

Journal of Clinical Psychopharmacology

Volumn 27, Issue 6, 2007, Pages 625-638

  Abanades, Sergio ^a,b   Farré, Magi ^a,b   Barral, Diego ^a   Torrens, Marta ^b,c   Closas, Neus ^a   Langohr, Klaus ^a,d   Pastor, Antoni ^a   De La Torre, Rafael ^a,e  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Institut d'Atenció Psiquiàtrica Salut Mental I Toxicomanies   (Spain)

^d UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^e UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; ALCOHOL; FLUNITRAZEPAM; PLACEBO; 4-HYDROXYBUTYRIC ACID; ANXIOLYTIC AGENT; CENTRAL DEPRESSANT AGENT; HYDROXYBUTYRIC ACID; UNCLASSIFIED DRUG;

ADDICTION RESEARCH CENTER INVENTORY 49 ITEM QUESTIONNAIRE; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; DRUG EFFECT; EUPHORIA; EVALUATION OF THE SUBJECTIVE EFFECT OF SUBSTANCE WITH POTENTIAL OF ABUSE QUESTIONNAIRE; HUMAN; MALE; MOUTH TEMPERATURE; MULTIPLE DRUG ABUSE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; PUPIL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SINGLE DRUG DOSE; TASK PERFORMANCE; VISUAL ANALOG SCALE; VITAL SIGN; ADDICTION; AREA UNDER THE CURVE; BLOOD PRESSURE; BODY TEMPERATURE; CHEMICALLY INDUCED DISORDER; DIVERGENT STRABISMUS; DOSE RESPONSE; HALF LIFE TIME; HEART RATE; MIOSIS; MYDRIASIS; ORAL DRUG ADMINISTRATION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; SWEATING; VOMITING;

ADMINISTRATION, ORAL; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOL; EXOTROPIA; FLUNITRAZEPAM; HALF-LIFE; HEART RATE; HUMANS; HYDROXYBUTYRATES; MALE; MIOSIS; MYDRIASIS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES; SUBSTANCE-RELATED DISORDERS; SWEATING; VOMITING;

EID: 39649095664     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e31815a2542     Document Type: Article

References (62)

1. Wong GT, Gibson KM, Snead OC 3rd. From street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci. 2004;25:29-34.
2. Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol. 1964;3:433-451.
3. Caputo F, Addolorato G, Lorenzini F, et al. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend. 2003;70:85-91.
4. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29:939-946.
5. Dyer JE. Gamma-hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med. 1991;9:321-324.
6. Chin RL, Sporer KA, Cullison B, et al. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med. 1998;31:716-722.
7. Varela M, Nogue S, Oros M, et al. Gamma hydroxybutyrate use for sexual assault. Emerg Med J. 2004;21:255-256.
8. Miotto K, Darakjian J, Basch J, et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict. 2001;10:232-241.
9. Degenhardt L, Darke S, Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend. 2002;67:89-94.
10. Gonzalez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol. 2005;19:195-204.
11. Beardsley PM, Balster RL, Harris LS. Evaluation of the discriminative stimulus and reinforcing effects of gammahydroxybutyrate (GHB). Psychopharmacology. 1996;127:315-322.
12. Winter JC. The stimulus properties of gamma-hydroxybutyrate. Psychopharmacology. 1981;73:372-375.
13. Woolverton WL, Rowlett JK, Winger G, et al. Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys. Drug Alcohol Depend. 1999:54;137-143.
14. Lobina C, Agabio R, Reali R, et al. Contribution of GABA-A and GABA-B receptors to the discriminative stimulus produced by gamma-hydroxybutyric acid. Pharmacol Biochem Behav. 1999;64:363-365.
15. Martellotta MC, Fattore L, Cossu G, et al. Rewarding properties of gamma-hydroxybutyric acid: an evaluation through place preference paradigm. Psychopharmacology. 1997;132:1-5.
16. Colombo G, Agabio R, Balaklievskaia N, et al. Oral self-administration of gammahydroxybutyric acid in the rat. Eur J Pharmacol. 1995;285:103-107.
17. Colombo G, Agabio R, Diaz G, et al. Gamma-hydroxybutyric acid intake in ethanol- preferring sP and -nonpreferring sNP rats. Physiol Behav. 1998;64:197-202.
18. Martellotta MC, Cossu G, Fattore L, et al. Intravenous self-administration of gamma-hydroxybutyric acid in drug-naive mice. Eur Neuropsychopharmacol. 1998;8:293-296.
19. Carter LP, Richards BD, Mintzer MZ, et al. Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology. 2006;31:2537-2551.
20. NIDA InfoFacts: Rohypnol and GHB. Available at: http://www.drugabuse.gov/ infofacts/RohypnolGHB.html. Accessed June 15, 2007.
21. Abanades S, Peiro AM, Farre M. Club drugs: old medicines as new party drugs. Med Clin (Barc). 2004;123:305-311.
22. Parks KA, Kennedy CL. Club drugs: reasons for and consequences of use. J Psychoactive Drugs. 2004;36:295-302.
23. Rosen MI, Pearsall HR, Woods SW, et al. Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients. J Subst Abuse Treat. 1997;14:149-154.
24. Ferrara SD, Giorgetti R, Zancaner S, et al. Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol. 1999;54:821-827.
25. Thai D, Dyer JE, Benowitz NL, et al. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol. 2006;26:524-529.
26. Abanades S, Farre M, Segura M, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci. 2006;1074:559-576.
27. Degenhardt L, Copeland J, Dillon P. Recent trends in the use of "club drugs": an Australian review. Subst Use Misuse. 2005;40:1241-1256.
28. Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 2003;70(3 suppl):S41-S54.
29. Wu LT, Schlenger WE, Galvin DM. Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend. 2006;84:102-113.
30. Farre M, Teran MT, Cami J. A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers. Psychopharmacology (Berl). 1996;125:1-12.
31. Roset PN, Farre M, de la Torre R, et al. Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. Drug Alcohol Depend. 2001;64:285-298.
32. Davidson D, Hutchison K, Dagon C, et al. Assessing the stimulant effects of alcohol in humans. Pharmacol Biochem Behav. 2002;72:151-156.
33. Pickworth WB, Fant RV, Bunker EB. Effects of abused drugs on papillary size and the light reflex. In: Karch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press; 1998:266-275.
34. Hernandez-Lopez C, Farre M, Roset PN, et al. 3,4- Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther. 2002;300:236-244.
35. Wechsler D. The Measurement and Appraisal of Adult Intelligence. Baltimore: Williams and Wilkins; 1958.
36. Hannington-Kiff JG. Measurement of recovery from out patient general anesthesia with a simple ocular test. BMJ. 1970;3:132-135.
37. Evans SM, Troisi JR II, Griffiths RR. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther. 1994;271:683-694.
38. Lamas X, Farré M, Llorente M, et al. Spanish version of the 49-item short version of the Addiction Research Center Inventory (ARCI). Drug Alcohol Depend. 1994;35:203-209.
39. Poudevida S, Farré M, Roset PN, et al. Construcción de un cuestionario para la Valoración de los Efectos Subjetivos de Sustancias con Potencial de Abuso (VESSPA): Evaluación del éxtasis. Adicciones. 2003;15:115-126.
40. Abanades S, Farré M, Segura M, et al. Disposition of GHB in conventional and non-conventional biological fluids after a single drug administration: issues in methodology and drug monitoring. Ther Drug Monit. 2007;29:64-70.
41. Farre M, de la Torre R, Llorente M, et al. Alcohol and cocaine interactions in humans. J Pharmacol Exp Ther. 1993;266:1364-1373.
42. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 1 - correlation within subjects. BMJ. 1995;310:446.
43. Miro O, Nogue S, Espinosa G, et al. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol. 2002;40:129-135.
44. Abanades S, Iglesias ML, Echarte JL, et al. Gammahydroxibutyrate: a novel toxicological emergency. Meth Find Clin Exp Pharmacol. 2001;23:326.
45. Liechti ME, Kupferschmidt H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly. 2004;134:534-537.
46. Degenhardt L, Darke S, Dillon P. The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. Addiction. 2003;98:199-204.
47. Mintzer MZ, Griffiths RR. An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers. Behav Pharmacol. 2005;16:579-584.
48. Roache JD, Cherek DR, Bennett RH, et al. Differential effects of triazolam and ethanol on awareness, memory, and psychomotor performance. J Clin Psychopharmacol. 1993;13:3-15.
49. Farre M, de la Torre R, Gonzalez ML, et al. Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. Pharmacol Exp Ther. 1997;283:164-176.
50. Walker DJ, Zacny JP. Lack of effects of ethanol pretreatment on the abuse liability of nitrous oxide in light and moderate drinkers. Addiction. 2001;96:1839-1845.
51. Holdstock L, de Wit H. Individual differences in the biphasic effects of ethanol. Alcohol Clin Exp Res. 1998;22:1903-1911.
52. Heishman SJ, Arasteh K, Stitzer ML. Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav. 1997;58:93-101.
53. Schuckit MA, Greenblatt D, Gold E, et al. Reactions to ethanol and diazepam in healthy young men. J Stud Alcohol. 1991;52:180-187.
54. Persson B, Henning M. Central cardiovascular effects of gamma-hydroxybutyric acid: interactions with noradrenaline, serotonin, dopamine and acetylcholine transmission. Acta Pharmacol Toxicol (Copenh). 1980;47:335-346.
55. Hicks AR, Kapusta DR, Varner KJ. Mechanisms underlying the sympathomimetic cardiovascular responses elicited by gamma-hydroxybutyrate. J Cardiovasc Pharmacol. 2004;44:631-638.
56. Couper FJ, Thatcher JE, Logan BK. Suspected GHB overdoses in the emergency department. J Anal Toxicol. 2004;28:481-484.
57. Espinosa G, Miro O, Nogue S, et al. Liquid ecstasy poisoning: study of 22 cases. Med Clin (Barc). 2001;117:56-58.
58. Palatini P, Tedeschi L, Frison G, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol. 1993;45:353-356.
59. Sporer KA, Chin RL, Dyer JE, et al. Gamma-hydroxybutyrate serum levels and clinical syndrome after severe overdose. Ann Emerg Med. 2003;42:3-8.
60. Scharf MB, Lai AA, Branigan B, et al. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep. 1998;21:507-514.
61. Borgen LA, Okerholm R, Morrison D, et al. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol. 2003;43:59-65.
62. Raybon JJ, Boje KM. Pharmacokinetics and pharmacodynamics of gamma-hydroxybutyric acid during tolerance in rats: effects on extracellular dopamine. J Pharmacol Exp Ther. 2007;320:1252-1260.